Physician profile
Gregory Mchugh
NPI 1023080843
$1,709.75
in general payments reported to CMS, 2019-2025
25 companies · $210 in 2025
The $210 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $727 · 2020: $297 · 2021: $135 · 2022: $43.38 · 2023: $161 · 2024: $136 · 2025: $210.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $507.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $507.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $258.81 | 2019-2025 | Breztri, Airsupra |
| Abbott Laboratories | $185.45 | 2019-2023 | Freestyle Libre 2 |
| Merck Sharp & Dohme LLC | $173.69 | 2019-2025 | Gardasil 9, Capvaxive |
| Novo Nordisk INC | $158.28 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Amarin Pharma, INC. | $119.35 | 2019-2021 | |
| Abbvie INC. | $118.69 | 2019-2023 | |
| Amgen INC. | $82.10 | 2019 | |
| Lilly USA, LLC | $76.84 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $60.88 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $59.73 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $57.28 | 2019-2022 | |
| Astellas Pharma US INC | $51.99 | 2024-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.08 | 2023-2025 | Ofev, Jardiance |
| Glaxosmithkline, LLC. | $42.66 | 2019-2023 | Shingrix, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $39.84 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $36.35 | 2019 | |
| Phathom Pharmaceuticals, INC. | $21.89 | 2024 | Voquezna |
| Sumitomo Pharma America, INC. | $17.55 | 2025 | Gemtesa |
| Teva Pharmaceuticals USA, INC. | $15.41 | 2020 | |
| Seqirus USA INC | $15.11 | 2019 | |
| Dexcom, INC. | $14.92 | 2024 | Dexcom G6 Transmitter |
| Hikma Pharmaceuticals USA | $13.93 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.24 | 2020 | |
| Allergan, INC. | $12.59 | 2019 | |
| Global Blood Therapeutics, INC. | $12.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Mchugh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.